Eschscholzia Study

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

February 15, 2026

Study Completion Date

February 15, 2026

Conditions
Sleep
Interventions
DRUG

Eschscholzia tablets

"The intervention will be provided as swallowable Eschscholzia tablets (1.0 g) containing 0.503g Eschscholzia californica Herba rec. tinct. conc. as the active pharmaceutical ingredient (API) corresponding 600 mg powdered herbal material."

DRUG

Placebo Tablets

A placebo tablet will be provided that matches the verum in its optical and sensorial properties and posology. Contains: microcrystalline cellulose, Colloidal anhydrous silica, glycerol distearate, caramel couleur and colorants.

Trial Locations (1)

1680

Diagnostics and Consultation Center Convex, Sofia

All Listed Sponsors
collaborator

DCC Convex Ltd.

UNKNOWN

lead

A. Vogel AG

INDUSTRY